Now in public beta

Every claim, checked against its source.

Alethic verifies that every claim in a paper is actually supported by what it cites, catching citation errors and unsupported claims before publication.

Try NowSee how it works
Verification Report
Illustrative example
Supported

“Editing efficiency exceeded 90% in the transfected cell line.”

Evidence

States this — the reported range contains the stated figure.

Cited reference [4]
Misstated

“No significant off-target effects were observed across all tested loci.”

Evidence

States something narrower — minimal activity at the loci tested, not all of them.

Cited reference [11]
Contradicted

“The method outperformed the comparator across every cell type tested.”

Evidence

States the opposite — the comparator scored higher in one tested cell type.

Cited reference [19]

Trusted by researchers at

uOttawaWaterlooUBCTorontoGWUUWUVAUMDNIHQueen'sWesternHowarduOttawaWaterlooUBCTorontoGWUUWUVAUMDNIHQueen'sWesternHoward
The platform

Verify every claim in a paper, end to end.

Upload a manuscript and Alethic decomposes it into atomic claims, retrieves each cited source, and audits citation fidelity, statistical consistency, and figure-text alignment, with full evidence trails behind every verdict.

Verification report · 2024

Efficacy of CRISPR-Cas9 in Mammalian Gene Therapy

Chen, L. · Nakamura, K. · Patel, R. · Williams, D. · Nature Biotechnology · 47/47 refs resolved
Sections
Abstract6
Introduction11
Methods18
Results34
Discussion34
Contradicted9Misstated10Needs a citation7Supported26
Introduction11 claims

Cas9 cuts both DNA strands three base pairs upstream of the PAM, leaving blunt ends.

12factual
Supported

Homology-directed repair is absent in post-mitotic cells, ruling out precise correction in neurons.

341 paper unavailablefactual
Misstated

One AAV vector can carry SpCas9, its guide RNA and a strong ubiquitous promoter.

67methodological
Contradicted
Contradicted

SpCas9, its guide RNA and a strong ubiquitous promoter fit in a single AAV vector.

0 of 2 cited papers we could read state this

[6]
Packaging limits of AAV vectors for in vivo genome editingContradicts

“SpCas9 with a ubiquitous promoter exceeds the 4.7 kb a single AAV genome can hold.”

[7]
Delivery routes for CRISPR nucleases in vivoDoesn't cover

Compares viral and lipid delivery; says nothing about AAV packaging limits.

Start verifying today

Every claim,
verified.

Join researchers at 12+ institutions already using Alethic to catch what peer review misses.

Try Now Talk to us